-
Mashup Score: 0
Further understanding of connective tissue disease-associated interstitial lung disease has opened doors for therapeutic options, but more work needs to be done in the field, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.Connective tissue disease-associated interstitial lung disease (CTD-ILD) can have “quite a diverse array of manifestations,” said
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
Vitamin D may be just one factor in the combination of “bad genes” and “bad luck” that causes autoimmune disease, according to a presenter at the 2020 Congress of Clinical Rheumatology-West. “There is evidence that vitamin D can affect the modulation and natural history of autoimmune diseases,” M. Eric Gershwin, MD, chief of the division of rheumatology,
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
“Does #VitaminD deficiency cause #autoimmune disease, or does autoimmune disease, and the associated treatments and medications, cause vitamin D deficiency?” a presenter asked attendees at #CCR2020 https://t.co/T6tY1X63aP
-
-
Mashup Score: 0Targeting bone marrow lesions may reduce osteoarthritis pain - 4 year(s) ago
Research linking fluctuations in bone marrow lesions with pain fluctuations may suggest that targeting these lesions could successfully reduce osteoarthritis pain, according to a speaker at the 2020 Congress of Clinical Rheumatology-West. “With the use of MRI, where you can see more than just bone and tissues but also changes in soft tissue, it has indeed become clear that specific
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
A #CCR2020 presenter noted that targeting #BoneMarrow lesions could successfully reduce #osteoarthritis pain https://t.co/5nwdonausj
-
-
Mashup Score: 0
IgG4-related disease treatment is expected evolve greatly over the next 3 to 5 years, with a trio of promising drugs — inebilizumab, rilzabrutinib and elotuzumab — on the horizon, according to a speaker at the 2020 Congress of Clinical Rheumatology-West. “The treatment of IgG4-related disease will look very different in the next 3-5 years, based on what we have come to
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
“The treatment of #IgG4 -related disease will look very different in the next 3-5 years” noted a presenter at #CCR2020 https://t.co/K9PsiFc1nQ
-
-
Mashup Score: 0
Advances in understanding of systemic juvenile idiopathic arthritis and adult-onset Still’s disease have elucidated the impact of biologic therapies on these conditions, according to a presenter at the 2020 Congress of Clinical Rheumatology-West. Peter Nigrovic, MD, attending physician in the rheumatology program at Boston Children’s Hospital and associate professor of
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
Blockade of both IL-1 with #canakinumab and IL-6 with #tocilizumab have been “transformative” in systemic juvenile #arthritis and adult-onset #StillsDisease noted a presenter at #CCR2020 https://t.co/R0fCUXnUpr
-
-
Mashup Score: 0
With judicious use, opioids may, in fact, have a role in managing chronic pain in the rheumatology setting, according to a presenter at the 2020 Congress of Clinical Rheumatology-West. “The root, long-term cause of the opioid crisis is based on trying to reduce pain, rather than trying to improve functioning” in patients with chronic conditions, said Daniel Doleys, PhD, director and
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
The #opioidcrisis crisis in the U.S. may be a misnomer, noted a #CCR2020 presenter. “What we have is a crisis of #drugs and #alcohol ." https://t.co/KQJ9DRl7hQ
-
-
Mashup Score: 0
Novel therapies are providing hope for more targeted therapy options in managing the myriad manifestations of psoriatic arthritis, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.“I tell patients: you are going to be unique,” Philip J. Mease, MD, of the Swedish Medical Center and the University of Washington, said in his presentation. “There is not
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
“In terms of unmet needs, we need to try to understand who is going to respond best to a #TNF inhibitor, a JAK inhibitor, IL-17, IL-23, rather than throwing a dart and picking a therapy,” Dr. Philip Mease told #CCR2020 attendees https://t.co/9hYLUsLKVn
-
-
Mashup Score: 0
A multidisciplinary approach is key to optimizing outcomes in systemic sclerosis, given the broad range of manifestations and organ systems that may be involved, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.“The pathological hallmarks of this disease are rather diverse,” Elizabeth R. Volkmann, MD, MS, director of the UCLA Scleroderma Program, and founder
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
A multidisciplinary approach is critical to improve outcomes in #scleroderma given the broad range of manifestations and organ systems that may be involved, noted a presenter at #CCR2020 https://t.co/RVxvCnVdiX
-
-
Mashup Score: 1
Recent landmark study results have shown that interleukin-6 blockade may be superior to prolonged prednisone therapy in giant cell arteritis, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.“The great majority of patients with GCA are unsuccessful in tapering their prednisone,” John H. Stone, MD, director of clinical rheumatology at Massachusetts General
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#CCR2020 presenter discusses how IL-6 may offer a better option to 'failed' #prednisone in for treating #GiantCellArteritis https://t.co/Wt8EVfUJa2
-
-
Mashup Score: 0Clinicians have 'a ways to go' in managing osteoporosis in women - 4 year(s) ago
Women with osteoporosis are not being identified and treated at sufficient rates, according to a presenter at the 2020 Congress of Clinical Rheumatology-West. Michael McClung, MD, founding director of the Oregon Osteoporosis Center, suggested that while novel therapeutic options do not cure osteoporosis, they can protect patients from fracture. But treatment must be ongoing.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
Women with #osteoporosis are not being identified and treated at sufficient rates, said Dr Michael McClung of the Oregon Osteoporosis Center at #CCR2020 West @CCRheumatology https://t.co/7HLP02Pm00
-
Overall, the connective tissue disease-associated interstitial lung disease treatment realm is an “evolving area,” according to a presenter at #CCR2020 https://t.co/Ulc4mo3omc